#ECTRIMS2022

#ECTRIMS2022 ā€“ Vumerity Lowers RRMS Activity Over 2 Years

Up to two years ofĀ Vumerity (diroximel fumarate) treatment was generally well-tolerated and led to significant decreases in disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to a final analysis of data from the open-label EVOLVE-MS-1 Phase 3 clinical trial. Indirect comparisons of Vumerity-treated patients against those…